M. Noris, J. Caprioli, E. Bresin, C. Mossali, G. Pianetti et al., Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype, Clin J Am Soc Nephrol, vol.5, pp.1844-1859, 2010.

T. K. Maga, C. J. Nishimura, A. E. Weaver, K. L. Frees, and R. J. Smith, Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome, Hum Mutat, vol.31, pp.1445-1460, 2010.

V. Fremeaux-bacchi, F. Fakhouri, A. Garnier, F. Bienaimé, M. A. Dragondurey et al., Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults, Clin J Am Soc Nephrol, vol.8, pp.554-562, 2013.

D. Kavanagh, T. H. Goodship, and A. Richards, Atypical hemolytic uremic syndrome, Semin Nephrol, vol.33, pp.508-530, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01793663

C. M. Nester and C. P. Thomas, Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated?, Hematology, vol.2012, pp.617-625, 2012.

J. M. Campistol, M. Arias, G. Ariceta, M. Blasco, M. Espinosa et al., An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document, Nefrologia, vol.33, pp.27-45, 2013.

S. R. Cataland and H. M. Wu, How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome, Blood, vol.123, pp.2478-2484, 2014.

M. Scully and T. Goodship, How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome, Br J Haematol, vol.164, pp.759-766, 2014.

M. Lemaire, V. Frémeaux-bacchi, F. Schaefer, M. Choi, W. H. Tang et al., Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome, Nat Genet, vol.45, pp.531-536, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01064383

G. Ariceta, N. Besbas, S. Johnson, D. Karpman, D. Landau et al., European Paediatric Study Group for HUS (2009) Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome, Pediatr Nephrol, vol.24, pp.687-696

S. Johnson, J. Stojanovic, G. Ariceta, M. Bitzan, N. Besbas et al., An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome, Pediatr Nephrol, vol.29, pp.1967-1978, 2014.

J. Zuber, F. Fakhouri, L. T. Roumenina, C. Loirat, V. Frémeaux-bacchi et al., Group for aHUS/C3G (2012) Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies, Nat Rev Nephrol, vol.8, pp.643-657

C. M. Legendre, C. Licht, P. Muus, L. A. Greenbaum, S. Babu et al., Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome, N Engl J Med, vol.368, pp.2169-2181, 2013.

E. K. Wong, T. H. Goodship, and D. Kavanagh, Complement therapy in atypical haemolytic uraemic syndrome (aHUS), Mol Immunol, vol.56, pp.199-212, 2013.

N. Besbas, D. Karpman, D. Landau, C. Loirat, W. Proesmans et al., European Paediatric Research Group for HUS (2006) A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders, Kidney Int, vol.70, pp.423-431

C. Loirat and V. Frémeaux-bacchi, Atypical hemolytic uremic syndrome, Orphanet J Rare Dis, vol.6, p.60, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-02157634

F. Fakhouri, M. Jablonski, J. Lepercq, J. Blouin, A. Benachi et al., Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome, Blood, vol.112, pp.4542-4545, 2008.

L. Quintrec, M. Lionet, A. Kamar, N. Karras, A. Barbier et al., Complement mutationassociated de novo thrombotic microangiopathy following kidney transplantation, Am J Transplant, vol.8, pp.1694-1701, 2008.

F. Fakhouri, L. Roumenina, F. Provot, M. Sallée, S. Caillard et al., Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations, J Am Soc Nephrol, vol.21, pp.859-867, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00512540

J. M. Spinale, R. L. Ruebner, B. S. Kaplan, and L. Copelovitch, Update on Streptococcus pneumoniae associated hemolytic uremic syndrome, Curr Opin Pediatr, vol.25, pp.203-208, 2013.

H. Yagi, M. Matsumoto, and Y. Fujimura, Paradigm shift of childhood thrombotic thrombocytopenic purpura with severe ADAM TS13 deficiency, Presse Med, vol.41, pp.137-155, 2012.

C. Loirat, P. Coppo, and A. Veyradier, Thrombotic thrombocytopenic purpura in children, Curr Opin Pediatr, vol.25, pp.216-224, 2013.

W. A. Hassenpflug, U. Budde, S. Schneppenheim, and R. Schneppenheim, Inherited thrombotic thrombocytopenic purpura in children, Semin Thromb Hemost, vol.40, pp.487-492, 2014.

J. A. Reese, D. S. Muthurajah, K. Hovinga, J. A. Vesely, S. K. Terrell et al., Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features, Pediatr Blood Cancer, vol.60, pp.1676-1682, 2013.

M. Hie, J. Gay, L. Galicier, F. Provôt, C. Presne et al., Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura, Thrombotic Microangiopathies Reference Centre, vol.124, pp.204-210, 2014.

E. Espié, F. Grimont, P. Mariani-kurkdjian, P. Bouvet, S. Haeghebaert et al., Surveillance of hemolytic uremic syndrome in children less than 15 years of age, a system to monitor O157 and non-O157 Shiga toxin-producing Escherichia coli infections in France, Pediatr Infect Dis J, vol.27, pp.595-601, 1996.

A. Rosales, J. Hofer, L. B. Zimmerhackl, T. C. Jungraithmayr, M. Riedl et al., Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late-emerging sequelae, Clin Infect Dis, vol.54, pp.1413-1421, 2012.

J. M. Spinale, R. L. Ruebner, L. Copelovitch, and B. S. Kaplan, Longterm outcomes of Shiga toxin hemolytic uremic syndrome, Pediatr Nephrol, vol.28, pp.2097-2105, 2013.

A. P. Sharma, C. R. Greenberg, A. N. Prasad, and C. Prasad, Hemolytic uremic syndrome (HUS) secondary to cobalamin C (cblC) disorder, Pediatr Nephrol, vol.22, pp.2097-2103, 2007.

F. Menni, S. Testa, S. Guez, G. Chiarelli, L. Alberti et al., Neonatal atypical hemolytic uremic syndrome due to methylmalonic aciduria and homocystinuria, Pediatr Nephrol, vol.27, pp.1401-1405, 2012.

C. Gall, E. Delmas, Y. , D. Parscau, L. Doucet et al., Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency, Am J Kidney Dis, vol.63, pp.119-123, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01011789

M. Kömhoff, M. T. Roofthooft, D. Westra, T. K. Teertstra, A. Losito et al., Combined pulmonary hypertension and renal thrombotic microangiopathy in cobalamin C deficiency, Pediatrics, vol.132, pp.540-544, 2013.

S. Fischer, M. Huemer, M. Baumgartner, F. Deodato, D. Ballhausen et al., Clinical presentation and outcome in a series of 88 patients with the cblC defect, J Inherit Metab Dis, vol.37, pp.831-840, 2014.

M. Huemer, S. Scholl-bürgi, K. Hadaya, I. Kern, R. Beer et al., Three new cases of late-onset cblC defect and review of the literature illustrating when to consider inborn errors of metabolism beyond infancy, Orphanet J Rare Dis, vol.9, p.161, 2014.

R. Peffault-de-latour, A. Xhaard, V. Fremeaux-bacchi, P. Coppo, A. M. Fischer et al., Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy, Br J Haematol, vol.161, pp.279-280, 2013.

S. Jodele, C. Licht, J. Goebel, B. P. Dixon, K. Zhang et al., Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy, Blood, vol.122, pp.2003-2007, 2013.

S. Jodele, T. Fukuda, A. Vinks, K. Mizuno, B. L. Laskin et al., Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy, Biol Blood Marrow Transplant, vol.20, pp.518-525, 2014.

A. Szilágyi, N. Kiss, C. Bereczki, G. Tálosi, K. Rácz et al., The role of complement in Streptococcus pneumoniae-associated haemolytic uraemic syndrome, Nephrol Dial Transplant, vol.28, pp.2237-2245, 2013.

R. D. Gilbert, A. Nagra, and M. R. Haq, Does dysregulated complement activation contribute to haemolytic uraemic syndrome secondary to Streptococcus pneumoniae?, Med Hypotheses, vol.81, pp.400-403, 2013.

K. Kokame, Y. Nobe, Y. Kokubo, A. Okayama, and T. Miyata, FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay, Br J Haematol, vol.129, pp.93-100, 2005.

I. Mackie, K. Langley, A. Chitolie, R. Liesner, M. Scully et al., Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies, Thromb Haemost, vol.109, pp.488-496, 2013.

S. Thouzeau, S. Capdenat, A. Stépanian, P. Coppo, and A. Veyradier, Evaluation of a commercial assay for ADAMTS13 activity measurement, Thromb Haemost, vol.110, pp.852-853, 2013.

M. Noris, S. Bucchioni, M. Galbusera, R. Donadelli, E. Bresin et al., International Registry of Recurrent and Familial HUS/TTP (2005) Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement, J Am Soc Nephrol, vol.16, pp.1177-1183

L. S. Keir and M. A. Saleem, Current evidence for the role of complement in the pathogenesis of Shiga toxin haemolytic uraemic syndrome, Pediatr Nephrol, vol.29, pp.1895-1902, 2014.

K. Poolpol, D. Orth-höller, C. Speth, P. F. Zipfel, C. Skerka et al., Interaction of Shiga toxin 2 with complement regulators of the factor H protein family, Mol Immunol, vol.58, pp.77-84, 2014.

V. Guigonis, V. Frémeaux-bacchi, S. Giraudier, R. Favier, D. Borderie et al., Lateonset thrombocytic microangiopathy caused by cblC disease: association with a factor H mutation, Am J Kidney Dis, vol.45, pp.588-595, 2005.

A. H. Bouts, M. T. Roofthooft, and G. S. Salomons, CD46-associated atypical hemolytic uremic syndrome with uncommon course caused by cblC deficiency, Pediatr Nephrol, vol.25, pp.2547-2548, 2010.

C. Loirat, J. Saland, and M. Bitzan, Management of hemolytic uremic syndrome, Presse Med, vol.41, pp.115-135, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-02149335

A. L. Ståhl, F. Vaziri-sani, S. Heinen, A. C. Kristoffersson, K. H. Gydell et al., Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation, Blood, vol.111, pp.5307-5315, 2008.

M. A. Dragon-durey, S. K. Sethi, A. Bagga, C. Blanc, J. Blouin et al., Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome, J Am Soc Nephrol, vol.21, pp.2180-2187, 2010.

J. Hofer, A. R. Janecke, L. B. Zimmerhackl, M. Riedl, A. Rosales et al., Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome, Clin J Am Soc Nephrol, vol.8, pp.407-415, 2013.

A. Sinha, A. Gulati, S. Saini, C. Blanc, A. Gupta et al., Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibodyassociated hemolytic uremic syndrome in children, Kidney Int, vol.85, pp.1151-1160, 2014.

C. Loirat and V. Fremeaux-bacchi, Anti-factor H autoantibodyassociated haemolytic uremic syndrome: the earlier diagnosed and treated, the better, Kidney Int, vol.85, pp.1019-1022, 2014.

J. Hofer, T. Giner, and M. Józsi, Complement factor h-antibodyassociated hemolytic uremic syndrome: pathogenesis, clinical presentation, and treatment, Semin Thromb Hemost, vol.40, pp.431-443, 2014.

M. Malina, A. Gulati, A. Bagga, M. A. Majid, E. Simkova et al., Peripheral gangrene in children with atypical hemolytic uremic syndrome, Pediatrics, vol.131, pp.331-335, 2013.

R. Westland, M. Bodria, A. Carrea, S. Lata, F. Scolari et al., Phenotypic expansion of DGKEassociated diseases, J Am Soc Nephrol, vol.25, pp.1408-1414, 2014.

D. Sánchez-chinchilla, S. Pinto, B. Hoppe, M. Adragna, L. Lopez et al., Complement mutations in diacylglycerol kinase-?-associated atypical hemolytic uremic syndrome, Clin J Am Soc Nephrol, vol.9, pp.1611-1619, 2014.

V. Fremeaux-bacchi, E. A. Moulton, D. Kavanagh, M. A. Dragon-durey, J. Blouin et al., Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome, J Am Soc Nephrol, vol.17, pp.2017-2025, 2006.

E. Bresin, E. Rurali, J. Caprioli, P. Sanchez-corral, V. Fremeaux-bacchi et al., European Working Party on Complement Genetics in Renal Diseases (2013) Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype, J Am Soc Nephrol, vol.24, pp.475-486

F. Bu, T. Maga, N. C. Meyer, K. Wang, C. P. Thomas et al., Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome, J Am Soc Nephrol, vol.25, pp.55-64, 2014.

S. Feng, S. J. Eyler, Y. Zhang, T. Maga, C. M. Nester et al., Afshar-Kharghan V (2013) Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome, Blood, vol.22, pp.1487-1493

I. Moore, L. Strain, I. Pappworth, D. Kavanagh, P. N. Barlow et al., Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome, Blood, vol.115, pp.379-387, 2010.

L. V. Holmes, L. Strain, S. J. Staniforth, I. Moore, K. Marchbank et al., Determining the population frequency of the CFHR3/CFHR1 deletion at 1q32, PLoS One, vol.8, p.60352, 2013.

S. E. Quaggin and . Dgke, Nat Genet, vol.45, pp.475-476, 2013.

L. M. Geerdink, D. Westra, J. A. Van-wijk, E. M. Dorresteijn, M. R. Lilien et al., Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics, Pediatr Nephrol, vol.27, pp.1283-1291, 2012.

S. R. Cataland, V. M. Holers, S. Geyer, S. Yang, and H. M. Wu, Biomarkers of the alternative pathway and terminal complement activity at presentation confirms the clinical diagnosis of aHUS and differentiates aHUS from TTP, Blood, vol.123, pp.3733-3738, 2014.

M. Noris, M. Galbusera, S. Gastoldi, P. Macor, F. Banterla et al., Dynamics of complement activation in aHUS and how to monitor eculizumab therapy, Blood, vol.124, pp.1715-1726, 2014.

E. B. Volokhina, D. Westra, T. J. Van-der-velden, N. C. Van-de-kar, T. E. Mollnes et al., Complement activation patterns in atypical hemolytic uremic syndrome during acute phase and in remission, Clin Exp Immunol, 2014.

R. Watson, S. Lindner, P. Bordereau, E. M. Hunze, F. Tak et al., Standardisation of the factor H autoantibody assay, Immunobiology, vol.219, pp.9-16, 2014.

L. Quintrec, M. Zuber, J. Moulin, B. Kamar, N. Jablonski et al., Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome, Am J Transplant, vol.13, pp.663-675, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00945715

J. Zuber, L. Quintrec, M. Krid, S. Bertoye, C. Gueutin et al., French Study Group for Atypical HUS (2012) Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation, Am J Transplant, vol.12, pp.3337-3354

P. Khandelwal, A. Sinha, P. Hari, V. K. Bansal, A. K. Dinda et al., Outcomes of renal transplant in patients with anticomplement factor H antibody-associated hemolytic uremic syndrome, Pediatr Transplant, vol.18, pp.134-139, 2014.

S. Sinibaldi, I. Guzzo, R. Piras, E. Bresin, F. Emma et al., Post-transplant recurrence of atypical hemolytic uremic syndrome in a patient with thrombomodulin mutation, Pediatr Transplant, vol.17, pp.177-181, 2013.

J. M. Saland, P. Ruggenenti, and G. Remuzzi, Liver-kidney transplantation to cure atypical hemolytic uremic syndrome, J Am Soc Nephrol, vol.20, pp.940-949, 2009.

, Soliris (eculizumab): EU summary of product characteristics, European Medicines Agency

, Soliris_ (eculizumab): US prescribing information, Alexion Pharmaceuticals Inc, vol.4, 2014.

C. Licht, L. A. Greenbaum, P. Muus, S. Babu, C. L. Bedrosian et al., Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome: 2-year results from extensions of phase 2 studies, Kidney Int, 2015.

C. Legendre, L. Greenbaum, N. Sheerin, D. Cohen, A. Gaber et al., Eculizumab efficacy in aHUS patients with progressing TMA, with or without prior renal transplant, 2013.

, Am J Transplant, vol.13, pp.278-279

L. A. Greenbaum, M. Fila, M. Tsimaratos, G. Ardissino, S. I. Al-akash et al., Eculizumab inhibits thrombotic microangiopathy and improves renal function in pediatric atypical hemolytic uremic syndrome patients, 2013.

, J Am Soc Nephrol, vol.24, pp.821-822

F. Fakhouri, M. Hourmant, C. Plana, J. M. Cataland, S. R. Espinosa et al., Eculizumab inhibits thrombotic microangiopathy, and improves renal function in adult atypical hemolytic uremic syndrome patients: 1-Year Update, 2014.

, J Am Soc Nephrol, vol.25, p.751

C. Loirat, C. M. Legendre, M. Ogawa, C. L. Bedrosian, J. Kincaid et al., Safety and efficacy of eculizumab in adult aHUS patients, with or without a history of renal transplant, 2014.

, J Am Soc Nephrol, vol.25, p.754

J. Rathbone, E. Kaltenthaler, A. Richards, P. Tappenden, A. Bessey et al., A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS), BMJ Open, vol.3, p.3573, 2013.

R. Vilalta, E. Lara, A. Madrid, S. Chocron, M. Muñoz et al., Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome, Pediatr Nephrol, vol.27, pp.2323-2326, 2012.

F. S. Cayci, N. Cakar, V. S. Hancer, N. Uncu, B. Acar et al., Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation, Pediatr Nephrol, vol.27, pp.2327-2331, 2012.

M. Giordano, G. Castellano, G. Messina, C. Divella, R. Bellantuono et al., Preservation of renal function in atypical hemolytic uremic syndrome by eculizumab: a case report, Pediatrics, vol.130, pp.1385-1388, 2012.

N. Besbas, B. Gulhan, D. Karpman, R. Topaloglu, A. Duzova et al., Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab, Pediatr Nephrol, vol.28, pp.155-158, 2013.

K. Gulleroglu, K. Fidan, V. S. Hançer, U. Bayrakci, E. Baskin et al., Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab, Pediatr Nephrol, vol.28, pp.827-830, 2013.

R. D. Gilbert, D. J. Fowler, A. E. Hardy, S. A. Stanley, L. Goodship et al., Eculizumab therapy for atypical haemolytic uraemic syndrome due to a gain-of-function mutation of complement factor B, Pediatr Nephrol, vol.28, pp.1315-1318, 2013.

M. H. Vaisbich, H. Ldos, S. Watanabe, A. Pereira, L. M. Metran et al., Eculizumab for the treatment of atypical hemolytic uremic syndrome: case report and revision of the literature, J Bras Nefrol, vol.35, pp.237-241, 2013.

H. Hu, A. Nagra, M. R. Haq, and R. D. Gilbert, Eculizumab in atypical haemolytic uraemic syndrome with severe cardiac and neurological involvement, Pediatr Nephrol, vol.29, pp.1103-1106, 2013.

M. Christmann, M. Hansen, C. Bergmann, D. Schwabe, J. Brand et al., Eculizumab as first-line therapy for atypical hemolytic uremic syndrome, Pediatrics, vol.133, pp.1759-1763, 2014.

K. Michaux, J. Bacchetta, E. Javouhey, P. Cochat, V. Frémaux-bacchi et al., Eculizumab in neonatal hemolytic uremic syndrome with homozygous factor H deficiency, Pediatr Nephrol, vol.29, pp.2415-2419, 2014.

F. Fakhouri, Y. Delmas, F. Provot, C. Barbet, A. Karras et al., Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases, Am J Kidney Dis, vol.63, pp.40-48, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-02162259

K. S. Hodgkins, A. E. Bobrowski, J. C. Lane, and C. B. Langman, Clinical grand rounds: atypical hemolytic uremic syndrome, Am J Nephrol, vol.35, pp.394-394, 2012.

N. Alachkar, S. M. Bagnasco, and R. A. Montgomery, Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft, Transpl Int, vol.25, pp.93-95, 2012.

S. Reuter, B. Heitplatz, H. Pavenstädt, and B. Suwelack, Successful long-term treatment of TMA with eculizumab in a transplanted patient with atypical hemolytic uremic syndrome due to MCP mutation, Transplantation, vol.96, pp.74-76, 2013.

J. Zuber, L. Quintrec, M. Morris, H. Frémeaux-bacchi, V. Loirat et al., Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation, Transplant Rev (Orlando), vol.27, pp.117-125, 2013.

L. Xie, C. M. Nester, A. I. Reed, Y. Zhang, R. J. Smith et al., Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report, Transplant Proc, vol.44, pp.3037-3040, 2012.

M. B. Pelicano, S. R. De-córdoba, F. Diekmann, M. Saiz, S. Herrero et al., Anti-C5 as prophylactic therapy in atypical hemolytic uremic syndrome in living-related kidney transplantation, Transplantation, vol.96, pp.26-29, 2013.

E. Román-ortiz, M. Oteiza, S. Pinto, S. López-trascasa, M. Sánchez-corral et al., Eculizumab long-term therapy for pediatric renal transplant in aHUS with CFH/CFHR1 hybrid gene, Pediatr Nephrol, vol.29, pp.149-153, 2014.

Z. D. Békássy, A. C. Kristoffersson, M. Cronqvist, L. T. Roumenina, T. Rybkine et al., Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesions, Nephrol Dial Transplant, vol.28, pp.2899-2907, 2013.

M. J. Walport, Complement. First of two parts, N Engl J Med, vol.344, pp.1058-1066, 2001.

T. M. Nolan, M. D. Nissen, A. Naz, J. Shepard, L. Bedell et al., Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age, Hum Vaccin Immunother, vol.10, pp.280-289, 2013.

A. Abdelnour, P. E. Silas, M. R. Lamas, C. F. Aragón, N. C. Chiu et al., Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants, Vaccine, vol.32, pp.965-972, 2014.

M. Zlamy, J. Hofer, J. Elias, U. Vogel, M. Frosch et al., Immunogenicity of meningococcus C vaccination in a patient with atypical hemolytic uremic syndrome (aHUS) on eculizumab therapy, Pediatr Transplant, vol.16, pp.246-250, 2012.

G. H. Struijk, A. H. Bouts, G. T. Rijkers, E. A. Kuin, I. J. Ten-berge et al., Meningococcal sepsis complicating eculizumab treatment despite prior vaccination, Am J Transplant, vol.13, pp.819-820, 2013.

P. Hillmen, P. Muus, A. Röth, M. O. Elebute, A. M. Risitano et al., Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria, Br J Haematol, vol.162, pp.62-73, 2013.

G. Sana, M. A. Dragon-durey, M. Charbit, K. Bouchireb, C. Roussetrouvière et al., Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses, Pediatr Nephrol, vol.29, pp.75-83, 2014.

D. Noone, A. Waters, F. G. Pluthero, D. F. Geary, M. Kirschfink et al., Successful treatment of DEAP-HUS with eculizumab, Pediatr Nephrol, vol.29, pp.841-851, 2014.

D. Chiodini, B. Davin, J. C. Corazza, F. Khaldi, K. Dahan et al., Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome, Pediatrics, vol.133, pp.1764-1768, 2014.

H. Green, E. Harari, M. Davidovits, D. Blickstein, A. Grossman et al., Atypical HUS due to factor H antibodies in an adult patient successfully treated with eculizumab, Ren Fail, vol.36, pp.1119-1121, 2014.

A. L. Sellier-leclerc, V. Fremeaux-bacchi, M. A. Dragon-durey, M. A. Macher, P. Niaudet et al., Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome, J Am Soc Nephrol, vol.18, pp.2392-2400, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-00409786

M. Réti, P. Farkas, D. Csuka, K. Rázsó, Á. Schlammadinger et al., Complement activation in thrombotic thrombocytopenic purpura, J Thromb Haemost, vol.10, pp.791-798, 2012.

M. Noris, F. Mescia, and G. Remuzzi, STEC-HUS, atypical HUS and TTP are all diseases of complement activation, Nat Rev Nephrol, vol.8, pp.622-633, 2012.

T. C. Wu, S. Yang, S. Haven, V. M. Holers, A. S. Lundberg et al., Complement activation and mortality during an acute episode of thrombotic thrombocytopenic purpura, J Thromb Haemost, vol.11, pp.1925-1927, 2013.

J. P. Westwood, K. Langley, E. Heelas, S. J. Machin, and M. Scully, Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura, Br J Haematol, vol.164, pp.858-856, 2014.

R. Tati, A. C. Kristoffersson, A. L. Ståhl, J. Rebetz, L. Wang et al., Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy, J Immunol, vol.191, pp.2184-2193, 2013.

J. Chapin, B. Weksler, C. Magro, and J. Laurence, Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura, Br J Haematol, vol.157, pp.772-774, 2012.

E. Tsai, J. Chapin, J. C. Laurence, and H. M. Tsai, Use of eculizumab in the treatment of a case of refractory, ADAMTS13-deficient thrombotic thrombocytopenic purpura: additional data and clinical follow-up, Br J Haematol, vol.162, pp.558-559, 2013.

M. Belingheri, I. Possenti, F. Tel, F. Paglialonga, S. Testa et al., Cryptic activity of atypical hemolytic uremic syndrome and eculizumab treatment, Pediatrics, vol.133, pp.1769-1771, 2014.

G. Ariceta, B. Arrizabalaga, M. Aguirre, E. Morteruel, and M. Lopez-trascasa, Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants, Am J Kidney Dis, vol.59, pp.707-710, 2012.

G. Ardissino, F. Tel, S. Testa, A. V. Marzano, R. Lazzari et al., Skin involvement in atypical hemolytic uremic syndrome, Am J Kidney Dis, vol.63, pp.652-655, 2013.

M. Ohanian, C. Cable, and K. Halka, Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome, Clin Pharmacol, vol.3, pp.5-12, 2011.

G. Salem, J. M. Flynn, and S. R. Cataland, Profound neurological injury in a patient with atypical hemolytic uremic syndrome, Ann Hematol, vol.92, pp.557-558, 2013.

F. Beye, C. Malbranche, D. Tramecon, C. Pernot, G. Zanetta et al., Eculizumab: effectiveness of a shortened dosing schedule in the treatment of atypical haemolytic uremic syndrome of unknown origin, Therapie, vol.68, pp.119-122, 2013.

J. J. Pu and A. Sido, Successful discontinuation of eculizumab therapy in a patient with aHUS, Ann Hematol, vol.93, pp.1423-1425, 2014.

P. Chaudhary, M. Hepgur, S. Sarkissian, R. J. Smith, and I. C. Weitz, Atypical haemolytic-uraemic syndrome due to heterozygous mutations of CFH/CFHR1-3 and complement factor H 479, Blood Transfus, vol.12, pp.111-113, 2014.

C. Loirat, M. A. Macher, M. Elmaleh-berges, T. Kwon, G. Deschênes et al., Non-atheromatous arterial stenoses in atypical haemolytic uraemic syndrome associated with complement dysregulation, Nephrol Dial Transplant, vol.25, pp.3421-3425, 2010.

J. C. Davin, C. Majoie, J. Groothoff, V. Gracchi, A. Bouts et al., Prevention of large-vessel stenoses in atypical hemolytic uremic syndrome associated with complement dysregulation, Pediatr Nephrol, vol.26, pp.155-157, 2011.

K. A?ukaitis, C. Loirat, M. Malina, I. Adomaitien?, and A. Jankauskien?, Macrovascular involvement in a child with atypical hemolytic uremic syndrome, Pediatr Nephrol, vol.29, pp.1273-1277, 2013.

M. Gargau, M. Azancot, R. Ramos, P. Sanchez-corral, M. A. Montero et al., Early treatment with eculizumab may be beneficial in atypical haemolytic uraemic syndrome, Clin Kidney J, vol.5, pp.1-3, 2012.

J. J. Kim, C. W. Simon, and C. J. Reid, Eculizumab in atypical haemolytic-uraemic syndrome allows cessation of plasma exchange and dialysis, Clin Kidney J, vol.0, pp.1-3, 2012.

H. Povey, R. Vundru, N. Junglee, and M. Jibani, Renal recovery with eculizumab in atypical hemolytic uremic syndrome following prolonged dialysis, Clin Nephrol, vol.82, pp.326-331, 2013.

M. Noris and G. Remuzzi, Cardiovascular complications in atypical haemolytic uraemic syndrome, Nat Rev Nephrol, vol.10, pp.174-180, 2014.

J. Nishimura, M. Yamamoto, S. Hayashi, K. Ohyashiki, K. Ando et al., Genetic variants in C5 and poor response to eculizumab, N Engl J Med, vol.370, pp.632-639, 2014.

M. Cugno, R. Gualtierotti, I. Possenti, S. Testa, F. Tel et al., Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome, J Thromb Haemost, vol.12, pp.1440-1448, 2014.

C. J. Mache, B. Acham-roschitz, V. Frémeaux-bacchi, M. Kirschfink, P. F. Zipfel et al., Complement inhibitor eculizumab in atypical hemolytic uremic syndrome, Clin J Am Soc Nephrol, vol.4, pp.1312-1316, 2009.

O. Köse, L. B. Zimmerhackl, T. Jungraithmayr, C. Mache, and J. Nürnberger, New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab, Semin Thromb Hemost, vol.36, pp.669-672, 2010.

R. Carr and S. R. Cataland, Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation, Ann Hematol, vol.92, pp.845-846, 2013.

Y. Delmas, C. Bordes, C. Loirat, V. Fremeaux-bacchi, and C. Combe, Post-partum atypical haemolytic uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice, Clin Kidney J, vol.6, pp.243-244, 2013.

C. Cañigral, F. Moscardó, C. Castro, A. Pajares, A. Lancharro et al., Eculizumab for the treatment of pregnancy-related atypical hemolytic uremic syndrome, Ann Hematol, vol.93, pp.1421-1422, 2014.

G. Ardissino, S. Testa, I. Possenti, F. Tel, F. Paglialonga et al., Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases, Am J Kidney Dis, vol.64, pp.633-637, 2014.

J. C. Verhave, D. Westra, H. W. Van-hamersvelt, M. Van-helden, N. C. Van-de-kar et al., Living kidney transplantation in adult patients with atypical haemolytic uraemic syndrome, Neth J Med, vol.71, pp.342-347, 2013.

T. A. Forbes, M. G. Bradbury, T. H. Goodship, P. J. Mckiernan, and D. V. Milford, Changing strategies for organ transplantation in atypical haemolytic uraemic syndrome: a tertiary case series, Pediatr Transplant, vol.17, pp.93-99, 2013.

J. Saland, Liver-kidney transplantation to cure atypical HUS: still an option post-eculizumab?, Pediatr Nephrol, vol.29, pp.329-332, 2014.

S. H. Park and G. S. Kim, Anesthetic management of living donor liver transplantation for complement factor H deficiency hemolytic uremic syndrome: a case report, Korean J Anesthesiol, vol.66, pp.481-485, 2014.